GSK Grows Immuno-Oncology Credentials With New Dostarlimab Indication

GlaxoSmithKline plc’s PD-1 blocking antibody, Jemperli (dostarlimab-gxly), has been approved for a second indication in the US, the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. This is a broader indication than the product’s first license for dMMR endometrial cancer, and marks the company’s continued drive to again become a major player in the cancer field. 

Jemperli has been associated with a 41.6% objective response rate (ORR) in patients with dMMR solid tumors in the ongoing GARNET study, with responses lasting for six months or longer, GSK noted